BRPI0607017A2 - métodos e composições para o tratamento de condições relacionadas ao snc - Google Patents
métodos e composições para o tratamento de condições relacionadas ao sncInfo
- Publication number
- BRPI0607017A2 BRPI0607017A2 BRPI0607017-5A BRPI0607017A BRPI0607017A2 BR PI0607017 A2 BRPI0607017 A2 BR PI0607017A2 BR PI0607017 A BRPI0607017 A BR PI0607017A BR PI0607017 A2 BRPI0607017 A2 BR PI0607017A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- methods
- related conditions
- snc
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
MéTODOS E COMPOSIçõES PARA O TRATAMENTO DE CONDIçõES RELACIONADAS AO SNC. A presente invenção fornece métodos e composições novos para o tratamento e prevenção de condições relacionadas ao SNG. Uma das condições relacionadas ao SNC tratada pelos métodos e composições da invenção é doença de Alzheimer.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66929005P | 2005-04-06 | 2005-04-06 | |
US60/669,290 | 2005-04-06 | ||
US11/285,905 US7619007B2 (en) | 2004-11-23 | 2005-11-22 | Method and composition for administering an NMDA receptor antagonist to a subject |
US11/285,905 | 2005-11-22 | ||
PCT/US2006/013506 WO2006121560A2 (en) | 2005-04-06 | 2006-04-06 | Methods and compositions for treatment of cns disorders |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0607017A2 true BRPI0607017A2 (pt) | 2009-08-04 |
BRPI0607017B1 BRPI0607017B1 (pt) | 2020-05-12 |
BRPI0607017B8 BRPI0607017B8 (pt) | 2021-05-25 |
Family
ID=37036831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0607017A BRPI0607017B8 (pt) | 2005-04-06 | 2006-04-06 | composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc |
Country Status (18)
Country | Link |
---|---|
US (18) | US8058291B2 (pt) |
EP (2) | EP1874282B1 (pt) |
JP (1) | JP5666087B2 (pt) |
KR (1) | KR101406456B1 (pt) |
CN (1) | CN101247795B (pt) |
AT (1) | ATE481096T1 (pt) |
AU (1) | AU2006244297A1 (pt) |
BR (1) | BRPI0607017B8 (pt) |
CA (1) | CA2604052C (pt) |
DE (1) | DE602006016934D1 (pt) |
DK (1) | DK1874282T3 (pt) |
HK (1) | HK1106711A1 (pt) |
IL (1) | IL186504A0 (pt) |
MX (1) | MX2007012374A (pt) |
PL (1) | PL1874282T3 (pt) |
RU (1) | RU2007140348A (pt) |
WO (1) | WO2006121560A2 (pt) |
ZA (1) | ZA200709535B (pt) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040122090A1 (en) * | 2001-12-07 | 2004-06-24 | Lipton Stuart A. | Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
AU2003298514A1 (en) * | 2002-05-17 | 2004-05-04 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
WO2005072705A1 (en) * | 2004-01-29 | 2005-08-11 | Neuromolecular, Inc. | Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions |
JP2007522248A (ja) * | 2004-02-13 | 2007-08-09 | ニューロモレキュラー・インコーポレイテッド | てんかんおよび他のcns障害の処置のための、nmdaレセプターアンタゴニストと抗てんかん薬との組み合わせ |
US7619007B2 (en) * | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
EP2623099A1 (en) | 2004-11-24 | 2013-08-07 | Neuromolecular Pharmaceuticals, Inc | Composition and method for treating neurological disease |
US20060160852A1 (en) * | 2004-12-27 | 2006-07-20 | Eisai Co. Ltd. | Composition containing anti-dementia drug |
US20060159753A1 (en) * | 2004-12-27 | 2006-07-20 | Eisai Co. Ltd. | Matrix type sustained-release preparation containing basic drug or salt thereof |
US8481565B2 (en) | 2004-12-27 | 2013-07-09 | Eisai R&D Management Co., Ltd. | Method for stabilizing anti-dementia drug |
PL1874282T3 (pl) | 2005-04-06 | 2011-04-29 | Adamas Pharmaceuticals Inc | Sposoby i kompozycje do leczenia zaburzeń OUN |
GB0519274D0 (en) * | 2005-09-21 | 2005-11-02 | Arakis Ltd | The treatment of neurodegenerative diseases |
US20090169617A1 (en) * | 2006-04-26 | 2009-07-02 | Panagiotis Keramidas | Controlled Release Formulations Comprising Uncoated Discrete Unit(s) and an Extended Release Matrix |
KR20090016611A (ko) * | 2006-07-05 | 2009-02-16 | 테바 파마슈티컬 인더스트리즈 리미티드 | 메만틴의 약학 조성물 |
GB0624757D0 (en) * | 2006-12-12 | 2007-01-17 | Sosei R & D Ltd | Novel compounds |
WO2009091932A2 (en) * | 2008-01-18 | 2009-07-23 | Adamas Pharmaceuticals, Inc. | Treatment of mild dementia of the alzheimer's disease type |
TWI491395B (zh) * | 2009-09-30 | 2015-07-11 | Ct Lab Inc | 一種內含用以治療神經退化性疾病之立即釋出與長效釋出藥物的口服劑量配方 |
EP3132793A1 (en) | 2009-12-02 | 2017-02-22 | Adamas Pharmaceuticals, Inc. | Amantadine compositions and methods of use |
EA037187B1 (ru) * | 2010-02-09 | 2021-02-17 | Дзе Джонс Хопкинс Юниверсити | Способ и композиция для лечения когнитивного расстройства |
US20110251239A1 (en) * | 2010-04-07 | 2011-10-13 | Eisai Inc. | Combination therapy for the treatment of dementia |
KR101351181B1 (ko) * | 2010-05-11 | 2014-01-14 | 가천대학교 산학협력단 | 단핵식세포계 세포 내에서 age-알부민의 합성 저해 또는 분비 저해에 의한 세포사 유도 저해 방법 |
DE102010024105A1 (de) * | 2010-06-17 | 2011-12-22 | Grünenthal GmbH | Transdermale Verabreichung von Memantin |
EP2588104B1 (en) | 2010-07-01 | 2014-12-10 | Merck Sharp & Dohme Corp. | Isoindolone m1 receptor positive allosteric modulators |
US20130209549A1 (en) * | 2010-07-21 | 2013-08-15 | University Of South Florida | Materials and methods for treating neurodegenerative diseases |
MX2013004123A (es) | 2010-10-12 | 2013-12-16 | Univ Johns Hopkins | Composiciones antitusigenas que comprenden memantina. |
DE102010053432A1 (de) * | 2010-12-06 | 2012-06-06 | Euroimmun Medizinische Labordiagnostika Ag | Verfahren zum Nachweis von anti-NMDA-Rezeptor Autoantikörpern zum Einsatz in Diagnoseverfahren |
EP3400934A1 (en) * | 2011-02-09 | 2018-11-14 | The Johns Hopkins University | Levetiracetam for improving cognitive function |
WO2012110912A1 (en) * | 2011-02-17 | 2012-08-23 | Lupin Limited | Sustained release composition of memantine |
JP6102739B2 (ja) * | 2011-08-31 | 2017-03-29 | 東洋インキScホールディングス株式会社 | 貼付剤 |
PL2838517T3 (pl) * | 2012-04-18 | 2018-03-30 | Contera Pharma Aps | Przeznaczony do podawania doustnego preparat farmaceutyczny na potrzeby udoskonalonego leczenia zaburzeń ruchowych |
MX2014015985A (es) | 2012-06-19 | 2015-07-21 | Univ Florida | Composiciones y metodos para tratar enfermedades. |
UA107653U (uk) | 2012-10-01 | 2016-06-24 | Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" | Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів |
US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
WO2014111790A2 (en) * | 2013-01-15 | 2014-07-24 | Zydus Technologies Limited | Stable transdermal pharmaceutical drug delivery system comprising rivastigmine |
KR102241113B1 (ko) * | 2013-02-28 | 2021-04-15 | 루핀 리미티드 | 특정한 체외 용해 프로파일 또는 약리역학 파라미터를 갖는 도네페질의 약제학적 조성물 |
EP2961392B1 (en) * | 2013-02-28 | 2020-10-28 | Lupin Limited | Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters |
WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
WO2014144801A1 (en) | 2013-03-15 | 2014-09-18 | Agenebio Inc. | Methods and compositions for improving cognitive function |
KR102424765B1 (ko) | 2013-04-12 | 2022-07-22 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 외상후 스트레스 장애의 치료 방법 |
WO2014204933A1 (en) | 2013-06-17 | 2014-12-24 | Adamas Pharmaceuticals, Inc. | Amantadine compositions and methods of use |
WO2015037019A2 (en) * | 2013-09-15 | 2015-03-19 | Rubicon Research Private Limited | Modified release pharmaceutical formulations |
JP6272353B2 (ja) * | 2013-12-12 | 2018-01-31 | 久光製薬株式会社 | カバー材付き貼付剤及びカバー材付き貼付剤キット |
EP3102186B1 (en) | 2014-02-04 | 2021-01-27 | Forest Laboratories Holdings Limited | Donepezil compositions and method of treating alzheimer's disease |
TWI602585B (zh) | 2014-03-25 | 2017-10-21 | 林信湧 | 一種用於治療阿茲海默症之吸入式醫藥組成物及其備製方法 |
AU2015327762C1 (en) * | 2014-10-03 | 2020-10-22 | Lachesis Biosciences Limited | Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders |
US9616068B2 (en) | 2014-10-27 | 2017-04-11 | Pohela LLC | Animal training using cognitive enhancement |
AU2015343199B2 (en) | 2014-11-04 | 2021-04-08 | Adamas Pharma, Llc | Methods of administering amantadine compositions |
ITUB20150635A1 (it) * | 2015-04-14 | 2016-10-14 | Giuseppe Lotito | Uso di un inibitore dell’aceticolinesterasi e composizioni farmaceutiche contenenti detto inibitore. |
EP3291815A4 (en) * | 2015-05-07 | 2019-01-16 | Axovant Sciences GmbH | METHODS OF TREATING NEURODEGENERATIVE DISEASE |
US10925834B2 (en) | 2015-05-22 | 2021-02-23 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
US20180244802A1 (en) * | 2015-08-17 | 2018-08-30 | Deutsches Zentrum Fur Neurodegenerative Erkrankungen E.V. (Dzne) | Antibody or antibody fragment of non-ig scaffold binding to a binding region of an anti-n-methyl-d-aspartate (nmda) receptor antibody |
KR101882224B1 (ko) * | 2015-09-02 | 2018-07-26 | 한국프라임제약주식회사 | 콜린 알포세레이트 및 메만틴을 함유하는 복합 조성물 |
CN105326837A (zh) * | 2015-10-09 | 2016-02-17 | 北京万全德众医药生物技术有限公司 | 一种盐酸美金刚缓释-多奈哌齐速释复方胶囊 |
EP3397253A1 (en) | 2015-12-30 | 2018-11-07 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of seizure-related disorders |
WO2017223402A1 (en) | 2016-06-23 | 2017-12-28 | Corium International, Inc. | Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent |
US9993466B2 (en) | 2016-07-27 | 2018-06-12 | Corium International, Inc. | Donepezil transdermal delivery system |
JP7469879B2 (ja) | 2016-07-27 | 2024-04-17 | コリウム, エルエルシー | 経口送達と生物学的に同等である薬物動態を有する経皮送達システム |
AU2017301929B2 (en) | 2016-07-27 | 2023-03-02 | Corium Pharma Solutions, Inc. | Memantine transdermal delivery systems |
WO2018062941A1 (ko) * | 2016-09-30 | 2018-04-05 | 주식회사 바이오파마티스 | 도네페질 또는 그의 약학적으로 허용 가능한 염 및 메만틴 또는 그의 약학적으로 허용 가능한 염을 함유하는 치매 및 인지기능 장애 예방 또는 치료용 약학 조성물 및 이의 제조방법 |
CN110325214A (zh) * | 2016-12-22 | 2019-10-11 | Rvx疗法有限公司 | 用于预防和治疗神经元损伤的低剂量药物组合 |
JP7317002B2 (ja) * | 2017-05-19 | 2023-07-28 | ビスケイン ニューロセラピューティクス,インコーポレイテッド | フペルジンの放出調節医薬組成物およびその使用方法 |
BR112020003375A2 (pt) | 2017-08-24 | 2020-08-25 | Adamas Pharma, Llc | composições de amantadina, preparações das mesmas, e métodos de uso |
JP7481794B2 (ja) | 2017-10-18 | 2024-05-13 | 日東電工株式会社 | ロール体 |
EP3713558A4 (en) * | 2017-11-22 | 2021-10-13 | Panorama Research Inc. | AMINO ADAMANTYL NITRATE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CNS DISEASES |
AU2018392686A1 (en) | 2017-12-20 | 2020-07-09 | Corium Pharma Solutions, Inc. | Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point |
KR102224918B1 (ko) * | 2018-03-20 | 2021-03-09 | (주)인벤티지랩 | 도네페질 및 메만틴을 포함하는 인지 장애 관련 질병의 예방 또는 치료용 약학적 복합 조성물 및 이의 제조 방법 |
WO2020208398A1 (es) | 2019-04-09 | 2020-10-15 | Laboratorios Bagó S.A. | Composición farmacéutica en polvo con memantina y donepecilo para utilizar en el tratamiento de la enfermedad de alzheimer |
US11602507B2 (en) | 2019-05-27 | 2023-03-14 | Trikona Pharmaceuticals Pvt. Ltd | Extended release oral composition of memantine or its salt and its process for the preparation |
HRP20231200T1 (hr) | 2019-05-31 | 2024-01-19 | Tecnimede, Sociedade Técnico-Medicinal, Sa | Kombinacija fiksne doze memantina i donepezila s trenutnim otpuštanjem |
JP2022538608A (ja) * | 2019-06-28 | 2022-09-05 | ザ トラスティーズ オヴ ザ ユニヴァーシティー オヴ ペンシルバニア | アルツハイマー病の治療のための鼻腔内ダントロレン投与 |
WO2021234475A1 (en) * | 2020-05-21 | 2021-11-25 | Pellets Pharma Limited | Modified release compositions and methods of memantine hcl extended release, donepezil hcl immediate release pellets |
CU20200087A7 (es) | 2020-11-24 | 2022-07-08 | Centro De Neurociencias De Cuba | Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer |
KR20240099388A (ko) * | 2021-11-01 | 2024-06-28 | 니트라제 테라퓨틱스, 인크. | 시누클레인병증의 진단 방법 |
WO2024099974A1 (en) * | 2022-11-07 | 2024-05-16 | Rejuvenate Biomed Nv | Galantamine minitablets |
Family Cites Families (163)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3152180A (en) | 1960-08-25 | 1964-10-06 | Studiengesellschaft Kohle Mbh | Process for the production of nu-tert-alkyl amides and, if desired, nu-tert. alkyl amines |
US3391142A (en) | 1966-02-09 | 1968-07-02 | Lilly Co Eli | Adamantyl secondary amines |
GB1175820A (en) | 1966-02-18 | 1969-12-23 | Upjohn Co | Amino-Adamantane Derivatives |
FR2219159A1 (en) | 1973-02-23 | 1974-09-20 | Commissariat Energie Atomique | Adamantane nitroxide radicals - antiviral and anticancer agents, also useful in nuclear resonance magnetometry |
US3992518A (en) | 1974-10-24 | 1976-11-16 | G. D. Searle & Co. | Method for making a microsealed delivery device |
US4284444A (en) | 1977-08-01 | 1981-08-18 | Herculite Protective Fabrics Corporation | Activated polymer materials and process for making same |
US4148896A (en) * | 1978-02-22 | 1979-04-10 | E. I. Du Pont De Nemours And Company | Antidepressant combination |
DE2856393C2 (de) * | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
IE52535B1 (en) * | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
DE3280308D1 (de) | 1981-04-24 | 1991-04-04 | Squibb & Sons Inc | Verwendung von nadolol zur herstellung peroraler formen fuer die behandlung von glaukom. |
US4346112A (en) | 1981-06-29 | 1982-08-24 | University Patents Inc. | Composition and method for treating patients having Parkinson's Disease |
JPS584718A (ja) | 1981-06-30 | 1983-01-11 | Nippon Chibagaigii Kk | 新規適応症に用うる医薬製剤 |
DK150008C (da) | 1981-11-20 | 1987-05-25 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat |
EP0190262B1 (en) | 1984-07-24 | 1990-12-27 | Key Pharmaceuticals, Inc. | Adhesive transdermal dosage layer |
US4769027A (en) * | 1984-08-15 | 1988-09-06 | Burroughs Wellcome Co. | Delivery system |
IL74497A (en) | 1985-03-05 | 1990-02-09 | Proterra Ag | Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives |
IT1188212B (it) | 1985-12-20 | 1988-01-07 | Paolo Colombo | Sistema per il rilascio a velocita' controllata di sostanze attive |
US4663318A (en) | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
ES2029805T3 (es) * | 1986-04-16 | 1992-10-01 | Asta Pharma Aktiengesellschaft | Procedimiento para preparar un producto que contiene amantadina y selegilina en asociacion sinergica. |
FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
US4861800A (en) * | 1987-08-18 | 1989-08-29 | Buyske Donald A | Method for administering the drug deprenyl so as to minimize the danger of side effects |
US4878913A (en) * | 1987-09-04 | 1989-11-07 | Pfizer Hospital Products Group, Inc. | Devices for neural signal transmission |
US4904681A (en) * | 1987-12-01 | 1990-02-27 | G. D. Searle & Co. | D-cycloserine and its prodrugs as cognitive enhancers |
GB8807504D0 (en) | 1988-03-29 | 1988-05-05 | Sandoz Ltd | Improvements in/relating to organic compounds |
US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
US5061721A (en) * | 1989-03-15 | 1991-10-29 | G. D. Searle & Co. | Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder |
US5334618A (en) | 1991-04-04 | 1994-08-02 | The Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
ATE94384T1 (de) * | 1989-04-14 | 1993-10-15 | Merz & Co Gmbh & Co | Verwendung von adamantan-derivaten zur praevention und behandlung der cerebralen ischaemie. |
WO1991006291A1 (en) | 1989-10-26 | 1991-05-16 | Nippon Shinyaku Co., Ltd. | Sustained release preparation |
CA2045175C (en) | 1989-11-06 | 2003-03-18 | Arthur I. Skoultchi | Production of proteins using homologous recombination |
IT1237904B (it) | 1989-12-14 | 1993-06-18 | Ubaldo Conte | Compresse a rilascio a velocita' controllata delle sostanze attive |
CA2037178A1 (en) | 1990-02-28 | 1991-08-29 | Albert Walter Brzeczko | Deprenyl/l-dopa/carbidopa pharmaceutical composition |
ZA911974B (en) | 1990-03-21 | 1994-08-22 | Res Dev Foundation | Heterovesicular liposomes |
US5190763A (en) * | 1990-05-07 | 1993-03-02 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
US5192550A (en) * | 1990-05-07 | 1993-03-09 | Alza Corporation | Dosage form for treating central nervous system disorders |
US5221536A (en) * | 1990-05-07 | 1993-06-22 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
US5057321A (en) * | 1990-06-13 | 1991-10-15 | Alza Corporation | Dosage form comprising drug and maltodextrin |
US5086072A (en) * | 1990-06-18 | 1992-02-04 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex |
IN172468B (pt) * | 1990-07-14 | 1993-08-14 | Asta Medica Ag | |
EP0488959A3 (en) | 1990-11-28 | 1992-08-05 | Sandoz Ltd. | New uses of competitive nmda receptor antagonists |
GB9104854D0 (en) | 1991-03-07 | 1991-04-17 | Reckitt & Colmann Prod Ltd | Sustained release compositions |
US5455279A (en) | 1991-04-19 | 1995-10-03 | The Children's Medical Center Corporation | Regimen method of mediating neuronal damage using nitroglycerine |
US5614560A (en) * | 1991-04-04 | 1997-03-25 | Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
US6764697B1 (en) | 1991-06-27 | 2004-07-20 | Alza Corporation | System for delaying drug delivery up to seven hours |
US5326570A (en) * | 1991-07-23 | 1994-07-05 | Pharmavene, Inc. | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine |
KR100221695B1 (ko) | 1991-08-12 | 1999-09-15 | 그린 마틴, 브라이언 쥐 테슬리 | 약학적 구상 제형 |
DE4225730C2 (de) * | 1992-08-04 | 2003-04-30 | Merz Pharma Gmbh & Co Kgaa | Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung |
DE4236752A1 (de) * | 1992-10-30 | 1994-05-05 | Asta Medica Ag | Kombinationspräparat aus Flupirtin und Morphin zur Behandlung von Schmerzen und zur Vermeidung der Morphin-Abhängigkeit |
US5358721A (en) * | 1992-12-04 | 1994-10-25 | Alza Corporation | Antiviral therapy |
CA2115792C (en) * | 1993-03-05 | 2005-11-01 | David J. Mayer | Method for the treatment of pain |
US5648087A (en) * | 1993-03-09 | 1997-07-15 | Sanofi Sante Nutrition Animale | Anaesthetic pharmaceutical composition comprising a general anaesthetic and selegiline |
AU676315B2 (en) * | 1993-06-30 | 1997-03-06 | Takeda Chemical Industries Ltd. | Stabilized solid pharmaceutical preparation and method of producing the same |
WO1995003052A1 (en) * | 1993-07-22 | 1995-02-02 | Warner-Lambert Company | Controlled release tacrine drug delivery systems and methods for preparing same |
US6908910B2 (en) | 1993-08-06 | 2005-06-21 | The Children's Medical Center Corporation | Estrogenic compounds as anti-mitotic agents |
NZ276305A (en) | 1993-11-16 | 1997-10-24 | Depotech Corp | Controlled release vesicle compositions |
US5395626A (en) | 1994-03-23 | 1995-03-07 | Ortho Pharmaceutical Corporation | Multilayered controlled release pharmaceutical dosage form |
US5484608A (en) * | 1994-03-28 | 1996-01-16 | Pharmavene, Inc. | Sustained-release drug delivery system |
US5660848A (en) | 1994-11-02 | 1997-08-26 | The Population Council, Center For Biomedical Research | Subdermally implantable device |
US20020006438A1 (en) | 1998-09-25 | 2002-01-17 | Benjamin Oshlack | Sustained release hydromorphone formulations exhibiting bimodal characteristics |
DE19510189A1 (de) | 1995-03-21 | 1996-09-26 | Hartmut Dr Goebel | Verwendung von Amantadin |
WO1996037226A2 (en) * | 1995-05-26 | 1996-11-28 | Pfizer Inc. | Combinations for the treatment of parkinsonism containing selective nmda antagonists |
US5677349A (en) * | 1995-04-27 | 1997-10-14 | Gilad; Gad M. | Agmatine for the treatment of neurotrauma and neurodegenerative diseases |
DE19528388A1 (de) * | 1995-08-02 | 1997-02-06 | Hans Peter Prof Dr Med Zenner | Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs |
AUPN605795A0 (en) | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
US6095148A (en) * | 1995-11-03 | 2000-08-01 | Children's Medical Center Corporation | Neuronal stimulation using electrically conducting polymers |
US6395292B2 (en) | 1996-02-02 | 2002-05-28 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
AU4078897A (en) | 1996-08-23 | 1998-03-06 | Algos Pharmaceutical Corporation | Anticonvulsant containing composition for treating neuropathic pain |
US5958919A (en) * | 1996-09-20 | 1999-09-28 | Washington University | Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration |
US5891885A (en) * | 1996-10-09 | 1999-04-06 | Algos Pharmaceutical Corporation | Method for treating migraine |
US5919826A (en) | 1996-10-24 | 1999-07-06 | Algos Pharmaceutical Corporation | Method of alleviating pain |
JP4863534B2 (ja) * | 1996-10-25 | 2012-01-25 | スパーナス ファーマシューティカルズ インコーポレイテッド | 可溶形態浸透用量送達システム |
DE19644998C1 (de) | 1996-10-30 | 1998-06-10 | Hanns Prof Dr Ludwig | Verwendung von Adamantanaminen oder strukturanaloger Verbindungen zur Bekämpfung von Borna Disease Virus und zur Prophylaxe und Behandlung von Affekterkrankungen und anderen mit BDV-Infektionen verbundenen Störungen bei Mensch und Tier |
US6919373B1 (en) | 1996-11-12 | 2005-07-19 | Alza Corporation | Methods and devices for providing prolonged drug therapy |
JPH10203966A (ja) | 1996-11-21 | 1998-08-04 | Takeda Chem Ind Ltd | 徐放性マイクロカプセルおよびその製造法 |
AU736308B2 (en) | 1996-12-20 | 2001-07-26 | Warner-Lambert Company Llc | Antitussive drugs delivered by ion exchange resins |
WO1998040337A1 (fr) | 1997-03-11 | 1998-09-17 | Daicel Chemical Industries, Ltd. | Derives d'adamantane et procede de production associe |
ES2175614T3 (es) | 1997-04-10 | 2002-11-16 | Pfizer | Derivados fluorosustituidos de adamantano. |
JP2001527554A (ja) * | 1997-05-07 | 2001-12-25 | アルゴス ファーマシューティカル コーポレーション | 抗うつ薬とnmdaレセプター拮抗薬とを組み合わせる神経障害痛の治療用組成物及び治療方法 |
MY125849A (en) | 1997-07-25 | 2006-08-30 | Alza Corp | Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems |
MA26553A1 (fr) * | 1997-10-17 | 2004-12-20 | Centaur Pharmaceuticals Inc | Alpha-aryl-n-alkylnitrones et compositions pharmaceutiques contenant ceux-la |
US6391922B1 (en) | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
US6007841A (en) * | 1998-03-13 | 1999-12-28 | Algos Pharmaceutical Corporation | Analgesic composition and method for treating pain |
DE19834764A1 (de) * | 1998-08-01 | 2000-02-03 | Univ Hannover | Mittel zur Stabilisierung von Lebensmitteln und kosmetischen Mitteln sowie Verfahren zu dessen Herstellung |
EA002720B1 (ru) | 1998-08-27 | 2002-08-29 | Фармациа Энд Апджон Аб | Терапевтическая композиция для введения толтеродина с контролируемым высвобождением и способ лечения мочевого пузыря с её использованием |
IL143691A0 (en) | 1998-12-17 | 2002-04-21 | Alza Corp | Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings |
US6797283B1 (en) | 1998-12-23 | 2004-09-28 | Alza Corporation | Gastric retention dosage form having multiple layers |
US8545880B2 (en) | 1999-02-26 | 2013-10-01 | Andrx Pharmaceuticals, Llc | Controlled release oral dosage form |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
ES2439274T3 (es) | 1999-03-03 | 2014-01-22 | Optinose As | Dispositivo de administración nasal |
SE9901077D0 (sv) * | 1999-03-23 | 1999-03-23 | Astra Ab | Novel use |
US6183770B1 (en) | 1999-04-15 | 2001-02-06 | Acutek International | Carrier patch for the delivery of agents to the skin |
US6743211B1 (en) * | 1999-11-23 | 2004-06-01 | Georgia Tech Research Corporation | Devices and methods for enhanced microneedle penetration of biological barriers |
CN100391438C (zh) | 1999-09-14 | 2008-06-04 | 史密丝克莱恩比彻姆公司 | 制备水性包被小球粒的方法 |
AU764453B2 (en) | 1999-10-29 | 2003-08-21 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
EP1231877A4 (en) * | 1999-11-04 | 2009-03-18 | Xel Herbaceuticals | TRANSDERMALE ADMINISTRATION OF HUPERZIN |
EP1239840B1 (en) * | 1999-12-09 | 2005-04-06 | Alza Corporation | Antiviral medication |
AU781839B2 (en) | 1999-12-22 | 2005-06-16 | Nektar Therapeutics | Sterically hindered derivatives of water soluble polymers |
US6491949B2 (en) * | 2000-01-14 | 2002-12-10 | Osmotica Corp. | Osmotic device within an osmotic device |
US6444702B1 (en) | 2000-02-22 | 2002-09-03 | Neuromolecular, Inc. | Aminoadamantane derivatives as therapeutic agents |
US6455066B1 (en) | 2000-03-10 | 2002-09-24 | Epicept Corporation | Intradermal-penetration agents for topical local anesthetic administration |
EP1559418A1 (en) | 2000-06-26 | 2005-08-03 | EpiCept Corporation | Compositions for treating pain of the mucous membrane |
US6648083B2 (en) | 2000-11-02 | 2003-11-18 | Schlumberger Technology Corporation | Method and apparatus for measuring mud and formation properties downhole |
US20040122090A1 (en) * | 2001-12-07 | 2004-06-24 | Lipton Stuart A. | Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
EP1389181A4 (en) * | 2001-04-02 | 2005-10-19 | Panorama Res Inc | ANTIOXIDANT NITROXIDES AND NITRONES AS THERAPEUTIC AGENTS |
DE10129265A1 (de) | 2001-06-18 | 2003-01-02 | Hf Arzneimittelforsch Gmbh | Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie |
US6500454B1 (en) | 2001-10-04 | 2002-12-31 | Eurand Pharmaceuticals Ltd. | Timed, sustained release systems for propranolol |
JP2005526079A (ja) * | 2002-03-15 | 2005-09-02 | サイプレス バイオサイエンス, インコーポレイテッド | 内蔵痛症候群を処置するためのneおよび5−ht再取り込み阻害剤 |
IL149055A0 (en) | 2002-04-09 | 2002-11-10 | Karma Pharm Ltd | Extended release composition comprising as active compound venlafaxine hydrochloride |
TW531966B (en) * | 2002-05-20 | 2003-05-11 | Mediatek Inc | Phase lock loop with low static state phase error and calibration circuit |
US20040102525A1 (en) * | 2002-05-22 | 2004-05-27 | Kozachuk Walter E. | Compositions and methods of treating neurological disease and providing neuroprotection |
WO2003101458A1 (en) | 2002-05-31 | 2003-12-11 | H. Lundbeck A/S | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease |
US6662845B1 (en) | 2002-06-19 | 2003-12-16 | Newell Operating Company | Roman shade with separated backing sheet |
US6945952B2 (en) * | 2002-06-25 | 2005-09-20 | Theraject, Inc. | Solid solution perforator for drug delivery and other applications |
BR0312429A (pt) | 2002-06-26 | 2005-04-19 | Alza Corp | Pistão de deformidade mìnima e de volume eficiente para sistemas de distribuição de drogas por osmose |
US20050208132A1 (en) * | 2002-07-29 | 2005-09-22 | Gayatri Sathyan | Methods and dosage forms for reducing side effects of benzisozazole derivatives |
ES2323268T3 (es) * | 2002-07-29 | 2009-07-10 | Glaxo Group Ltd | Formulaciones de liberacion prolongada que contienen lamotrigina. |
US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
US6913768B2 (en) | 2002-09-24 | 2005-07-05 | Shire Laboratories, Inc. | Sustained release delivery of amphetamine salts |
US20050075679A1 (en) * | 2002-09-30 | 2005-04-07 | Gliner Bradford E. | Methods and apparatuses for treating neurological disorders by electrically stimulating cells implanted in the nervous system |
KR100852834B1 (ko) | 2002-10-24 | 2008-08-18 | 메르츠 파마 게엠베하 운트 코. 카가아 | 1-아미노시클로헥산 유도체 및 아세틸콜린에스테라제저해제를 포함하는 약학적 제품 및 이를 이용한 복합 치료 |
JP2006510655A (ja) * | 2002-12-11 | 2006-03-30 | ファイザー・プロダクツ・インク | 高脂肪環境への活性物質の制御放出 |
US20040224020A1 (en) * | 2002-12-18 | 2004-11-11 | Schoenhard Grant L. | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats |
WO2004056335A2 (es) | 2002-12-23 | 2004-07-08 | Osmotica Costa Rica Sociedad Anonima | Dispositivo de liberación que contiene venlafaxina y memantina |
US20050031651A1 (en) * | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
ES2214129B1 (es) * | 2003-02-13 | 2005-12-01 | Almirall Prodesfarma, S.A. | 3-fenilfuran-2-onas. |
AR043467A1 (es) * | 2003-03-05 | 2005-07-27 | Osmotica Argentina S A | Combinacion de drogas para la disfuncion motora en la enfermedad de parkinson |
US20050065219A1 (en) * | 2003-03-27 | 2005-03-24 | Lipton Stuart A. | Treatment of demyelinating conditions |
WO2004099161A1 (en) * | 2003-05-09 | 2004-11-18 | Pharmacia & Upjohn Company Llc | Pyrazinones as crf1 receptor antagonists for the treatment of cns disorders |
US20050124701A1 (en) * | 2003-06-11 | 2005-06-09 | Went Gregory T. | Method of targeting a therapeutic agent |
JP2006527774A (ja) | 2003-06-16 | 2006-12-07 | アラーガン、インコーポレイテッド | メマンチン経口製剤 |
US20060079578A1 (en) * | 2003-06-23 | 2006-04-13 | Julie Laurin | Pharmaceutical formulations of amyloid inhibiting compounds |
KR100524018B1 (ko) * | 2003-07-25 | 2005-10-26 | 삼성전자주식회사 | 이동형 디스플레이장치 및 이동형 디스플레이 시스템 |
US20050037364A1 (en) * | 2003-08-13 | 2005-02-17 | International Business Machines Corporation | Techniques for recording signals |
WO2005079779A1 (en) | 2003-10-22 | 2005-09-01 | Merz Pharma Gmbh & Co. Kgaa | THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC Aß PEPTIDES IN AMYLOIDOPATHIES |
JP2007512338A (ja) * | 2003-11-21 | 2007-05-17 | メモリー・ファーマシューティカルズ・コーポレイション | L型カルシウムチャンネルブロッカーとコリンエステラーゼ阻害剤を用いた組成物及び処置方法 |
US20050119249A1 (en) * | 2003-12-02 | 2005-06-02 | Erik Buntinx | Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
US7553858B2 (en) | 2003-12-17 | 2009-06-30 | Meda Pharma Gmbh & Co. Kg | Combination of flupirtine and tramadol |
US20050191349A1 (en) * | 2003-12-31 | 2005-09-01 | Garth Boehm | Galantamine formulations |
EP1776089A2 (en) * | 2003-12-31 | 2007-04-25 | Actavis Group hf | Donepezil formulations |
DE602005024511D1 (de) | 2004-01-05 | 2010-12-16 | Merz Pharma Gmbh & Co Kgaa | Memantin für die behandlung von leichtem bis mittelschwerem morbus alzheimer |
WO2005072705A1 (en) | 2004-01-29 | 2005-08-11 | Neuromolecular, Inc. | Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions |
AU2005215775B2 (en) * | 2004-02-13 | 2011-02-03 | Neuromolecular, Inc. | Combination of a NMDA receptor antagonist and an anti-depressive drug MAO-inhibitor or a GADPH-inhibitor for the treatment of psychiatric conditions |
JP2007522248A (ja) | 2004-02-13 | 2007-08-09 | ニューロモレキュラー・インコーポレイテッド | てんかんおよび他のcns障害の処置のための、nmdaレセプターアンタゴニストと抗てんかん薬との組み合わせ |
DE602005018763D1 (de) | 2004-02-18 | 2010-02-25 | Sepracor Inc | Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität |
TW200531680A (en) | 2004-03-03 | 2005-10-01 | Merz Pharma Gmbh & Co Kgaa | Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease |
EP1740172A4 (en) | 2004-03-19 | 2007-10-10 | Axonyx Inc | ACETYLCHOLINESTERASE INHIBITORS AND N-METHYL-D-ASPARTATE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DISORDER |
US20060002999A1 (en) | 2004-06-17 | 2006-01-05 | Forest Laboratories, Inc. | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane |
CA2569015A1 (en) * | 2004-06-17 | 2006-01-26 | Forest Laboratories, Inc. | Modified release formulation of memantine |
US7346382B2 (en) * | 2004-07-07 | 2008-03-18 | The Cleveland Clinic Foundation | Brain stimulation models, systems, devices, and methods |
WO2006024018A2 (en) * | 2004-08-24 | 2006-03-02 | Neuromolecular Pharmaceuticals, Inc. | Compositions for treating nociceptive pain |
US20060240043A1 (en) * | 2004-10-08 | 2006-10-26 | Meyerson Laurence R | Methods and compositions for treating migraine pain |
US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
EP2623099A1 (en) * | 2004-11-24 | 2013-08-07 | Neuromolecular Pharmaceuticals, Inc | Composition and method for treating neurological disease |
US8252331B2 (en) * | 2004-12-03 | 2012-08-28 | Osmotica Kereskedelmi és Szolgáltató, KFT | Osmotic device containing amantadine and an osmotic salt |
AR053986A1 (es) | 2004-12-03 | 2007-05-30 | Osmotica Pharmaceutical Argent | Dispositivo osmotico que contiene amantadina y una sal osmotica |
US20090208579A1 (en) * | 2004-12-27 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
US20060246003A1 (en) * | 2004-12-27 | 2006-11-02 | Eisai Co. Ltd. | Composition containing anti-dementia drug |
US20060160852A1 (en) * | 2004-12-27 | 2006-07-20 | Eisai Co. Ltd. | Composition containing anti-dementia drug |
US20080279819A1 (en) * | 2005-02-15 | 2008-11-13 | Adamas Pharmaceuticals, Inc. | Combinations Therapy for Treatment of Demyelinating Conditions |
PL1874282T3 (pl) | 2005-04-06 | 2011-04-29 | Adamas Pharmaceuticals Inc | Sposoby i kompozycje do leczenia zaburzeń OUN |
CA2607600A1 (en) | 2005-06-16 | 2006-12-28 | Forest Laboratories, Inc. | Modified and immediate release memantine bead formulation |
ES2521494T3 (es) | 2007-04-02 | 2014-11-12 | Parkinson's Institute | Métodos y composiciones para la reducción de los efectos secundarios de tratamientos terapéuticos |
-
2006
- 2006-04-06 PL PL06749777T patent/PL1874282T3/pl unknown
- 2006-04-06 CA CA2604052A patent/CA2604052C/en active Active
- 2006-04-06 EP EP06749777A patent/EP1874282B1/en not_active Revoked
- 2006-04-06 WO PCT/US2006/013506 patent/WO2006121560A2/en active Application Filing
- 2006-04-06 AT AT06749777T patent/ATE481096T1/de not_active IP Right Cessation
- 2006-04-06 CN CN2006800166301A patent/CN101247795B/zh active Active
- 2006-04-06 JP JP2008505658A patent/JP5666087B2/ja active Active
- 2006-04-06 EP EP10075323.5A patent/EP2243475B1/en active Active
- 2006-04-06 AU AU2006244297A patent/AU2006244297A1/en not_active Abandoned
- 2006-04-06 US US11/399,879 patent/US8058291B2/en active Active
- 2006-04-06 BR BRPI0607017A patent/BRPI0607017B8/pt active IP Right Grant
- 2006-04-06 RU RU2007140348/15A patent/RU2007140348A/ru not_active Application Discontinuation
- 2006-04-06 DK DK06749777.6T patent/DK1874282T3/da active
- 2006-04-06 KR KR1020077025686A patent/KR101406456B1/ko active IP Right Grant
- 2006-04-06 DE DE602006016934T patent/DE602006016934D1/de active Active
- 2006-04-06 MX MX2007012374A patent/MX2007012374A/es active IP Right Grant
-
2007
- 2007-10-08 IL IL186504A patent/IL186504A0/en unknown
- 2007-11-06 ZA ZA200709535A patent/ZA200709535B/xx unknown
-
2008
- 2008-01-10 HK HK08100318.7A patent/HK1106711A1/xx not_active IP Right Cessation
-
2010
- 2010-04-02 US US12/753,769 patent/US8293794B2/en active Active
- 2010-04-09 US US12/757,795 patent/US8283379B2/en active Active
-
2012
- 2012-06-28 US US13/536,763 patent/US8338486B2/en active Active
- 2012-06-28 US US13/536,588 patent/US8338485B2/en active Active
- 2012-07-26 US US13/559,478 patent/US20120288560A1/en not_active Abandoned
- 2012-12-21 US US13/725,246 patent/US8580858B2/en active Active
-
2013
- 2013-04-15 US US13/863,140 patent/US20140134243A1/en not_active Abandoned
-
2015
- 2015-02-03 US US14/613,220 patent/US20150297537A1/en not_active Abandoned
-
2016
- 2016-04-04 US US15/090,429 patent/US20160243093A1/en not_active Abandoned
- 2016-04-04 US US15/090,400 patent/US20160250149A1/en not_active Abandoned
- 2016-04-04 US US15/090,416 patent/US20160220545A1/en not_active Abandoned
- 2016-04-04 US US15/090,396 patent/US20160243035A1/en not_active Abandoned
- 2016-04-29 US US15/142,253 patent/US20160243095A1/en not_active Abandoned
- 2016-04-29 US US15/142,519 patent/US20160243058A1/en not_active Abandoned
- 2016-04-29 US US15/142,133 patent/US20160243094A1/en not_active Abandoned
- 2016-04-29 US US15/142,492 patent/US20160250161A1/en not_active Abandoned
-
2017
- 2017-10-23 US US15/790,710 patent/US20180263914A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0607017A2 (pt) | métodos e composições para o tratamento de condições relacionadas ao snc | |
BRPI0506736A (pt) | composto estereoisoméricos e métodos para o tratamento de distúrbios gastrointestinais e no sistema nervoso central | |
ATE492542T1 (de) | Herstellung und anwendung von biphenyl-4-yl- carbonylaminosäurederivaten zur behandlung von obesitas | |
DE602006018057D1 (de) | Substituierte chinolone und verwendungsverfahren | |
TW200510334A (en) | Preraration and use of aryl alkyl acid derivatives for the treatment of obesity | |
ATE416761T1 (de) | Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund | |
EA200801481A1 (ru) | 5-(арилсульфонил)пиразолопиперидины | |
ECSP066986A (es) | Beta-carbolinas utiles para tratar enfermedades inflamatorias | |
BRPI0515528A (pt) | n-metil hidroxietilamina úteis no tratamento de condições do sistema nervoso central | |
WO2010075280A3 (en) | Coumarin-based compounds for the treatment of alzheimer's disease and cancer | |
ATE446754T1 (de) | Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten | |
ATE362374T1 (de) | Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust | |
TW200735868A (en) | Compositions and methods for treating CNS disorders | |
ATE459353T1 (de) | Gaboxadol zur behandlung von depressionen und anderen affektiven störungen | |
EA200701584A1 (ru) | Органические соединения, применяемые для лечения болезни альцгеймера, их применение и способ получения | |
WO2009043858A3 (en) | Methods for treating and diagnosing a cancer secreting cath-d or alzheimer's disease | |
DE602004020741D1 (de) | Mittel zur behandlung der allergischen kontaktdermatitis | |
BRPI0509881A (pt) | combinação terapêutica para tratamento da doença de alzheimer | |
EA200702479A1 (ru) | Активная композиция для лечения и профилактики расстройств, связанных с нарушением работы биологических часов | |
DE60203026D1 (de) | Sulfonylpyridazinone Derivate zur Behandlung von ischämischem Gewebeschaden | |
ATE480234T1 (de) | Indolonverbindungen zur behandlung kognitiver schwächen | |
BRPI0515383A (pt) | n-etil hidroxietilamina útil no tratamento de condições do snc | |
DOP2003000728A (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenetivos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/05/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/04/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |